{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T20:04:33Z","timestamp":1779739473237,"version":"3.53.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,19]],"date-time":"2011-07-19T00:00:00Z","timestamp":1311033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"},{"start":{"date-parts":[[2011,7,19]],"date-time":"2011-07-19T00:00:00Z","timestamp":1311033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Syst Biol"],"published-print":{"date-parts":[[2011,7,19]]},"DOI":"10.1038\/msb.2011.47","type":"journal-article","created":{"date-parts":[[2011,7,19]],"date-time":"2011-07-19T10:55:55Z","timestamp":1311072955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["A pharmacogenomic method for individualized prediction of drug sensitivity"],"prefix":"10.1038","volume":"7","author":[{"given":"Adam L","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Soldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan E","family":"Welm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avrum","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie S","family":"Jeffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea H","family":"Bild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,19]]},"reference":[{"key":"BFMSB201147_CR1","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1158\/1078-0432.CCR-08-2035","volume":"15","author":"AA Adjei","year":"2009","unstructured":"Adjei AA, Christian M, Ivy P (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15: 1866\u20131872","journal-title":"Clin Cancer Res"},{"key":"BFMSB201147_CR2","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-07-0539","volume":"67","author":"G Alexe","year":"2007","unstructured":"Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, Harris L, Barnard N, Martel M, Levine AJ, Ganesan S, Bhanot G (2007) High expression of lymphocyte\u2010associated genes in node\u2010negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 67: 10669\u201310676","journal-title":"Cancer Res"},{"key":"BFMSB201147_CR3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1634\/theoncologist.2008-0288","volume":"14","author":"JJ Barron","year":"2009","unstructured":"Barron JJ, Cziraky MJ, Weisman T, Hicks DG (2009) HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist 14: 760\u2013768","journal-title":"Oncologist"},{"key":"BFMSB201147_CR4","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1056\/NEJMe048300","volume":"351","author":"RC Bast Jr","year":"2004","unstructured":"Bast Jr RC, Hortobagyi GN (2004) Individualized care for patients with cancer\u2014a work in progress. N Engl J Med 351: 2865\u20132867","journal-title":"N Engl J Med"},{"key":"BFMSB201147_CR5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","volume":"439","author":"AH Bild","year":"2006","unstructured":"Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson Jr JA, Marks JR, Dressman HK, West M, Nevins JR (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353\u2013357","journal-title":"Nature"},{"key":"BFMSB201147_CR6","first-page":"17","volume":"7","author":"MJ Bissell","year":"2005","unstructured":"Bissell MJ, Labarge MA (2005) Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7: 17\u201323","journal-title":"Cancer Cell"},{"key":"BFMSB201147_CR7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(03)14023-8","volume":"362","author":"JC Chang","year":"2003","unstructured":"Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362\u2013369","journal-title":"Lancet"},{"key":"BFMSB201147_CR8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clon.2010.02.011","volume":"22","author":"SG Coulson","year":"2010","unstructured":"Coulson SG, Kumar VS, Manifold IM, Hatton MQ, Ramakrishnan S, Dunn KS, Purohit OP, Bridgewater C, Coleman RE (2010) Review of testing and use of adjuvant trastuzumab across a cancer network\u2014are we treating the right patients? Clin Oncol (R Coll Radiol) 22: 289\u2013293","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"BFMSB201147_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2407-6-177","volume":"6","author":"V Dam","year":"2006","unstructured":"Dam V, Morgan BT, Mazanek P, Hogarty MD (2006) Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer 6: 177","journal-title":"BMC Cancer"},{"key":"BFMSB201147_CR10","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-09-2167","volume":"16","author":"JE Dancey","year":"2010","unstructured":"Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR (2010) Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16: 1745\u20131755","journal-title":"Clin Cancer Res"},{"key":"BFMSB201147_CR11","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1016\/j.ejca.2008.09.011","volume":"44","author":"C Desmedt","year":"2008","unstructured":"Desmedt C, Ruiz\u2010Garcia E, Andre F (2008) Gene expression predictors in breast cancer: current status, limitations and perspectives. Eur J Cancer 44: 2714\u20132720","journal-title":"Eur J Cancer"},{"key":"BFMSB201147_CR12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrclinonc.2009.234","volume":"7","author":"S Di Cosimo","year":"2010","unstructured":"Di Cosimo S, Baselga J (2010) Management of breast cancer with targeted agents: importance of heterogeneity [corrected]. Nat Rev Clin Oncol 7: 139\u2013147","journal-title":"Nat Rev Clin Oncol"},{"key":"BFMSB201147_CR13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/439274a","volume":"439","author":"J Downward","year":"2006","unstructured":"Downward J (2006) Cancer biology: signatures guide drug choice. Nature 439: 274\u2013275","journal-title":"Nature"},{"key":"BFMSB201147_CR14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nbt.1513","volume":"27","author":"J Du","year":"2009","unstructured":"Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR (2009) Bead\u2010based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27: 77\u201383","journal-title":"Nat Biotechnol"},{"key":"BFMSB201147_CR15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2007.02.006","volume":"254","author":"PR Dutta","year":"2007","unstructured":"Dutta PR, Maity A (2007) Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254: 165\u2013177","journal-title":"Cancer Lett"},{"key":"BFMSB201147_CR16","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","volume":"177","author":"FJ Esteva","year":"2010","unstructured":"Esteva FJ, Guo H, Zhang S, Santa\u2010Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D (2010) PTEN, PIK3CA, p\u2010AKT, and p\u2010p70S6K status: association with trastuzumab response and survival in patients with HER2\u2010positive metastatic breast cancer. Am J Pathol 177: 1647\u20131656","journal-title":"Am J Pathol"},{"key":"BFMSB201147_CR17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/01480549109011640","volume":"14","author":"R Fisher","year":"1991","unstructured":"Fisher R, Nau H, Gandolfi AJ, Putnam CW, Brendel K (1991) Valproic acid hepatotoxicity in human liver slices. Drug Chem Toxicol 14: 375\u2013394","journal-title":"Drug Chem Toxicol"},{"key":"BFMSB201147_CR18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809\u2013819","journal-title":"N Engl J Med"},{"key":"BFMSB201147_CR19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.drudis.2008.03.003","volume":"13","author":"JA Foekens","year":"2008","unstructured":"Foekens JA, Wang Y, Martens JW, Berns EM, Klijn JG (2008) The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. Drug Discov Today 13: 481\u2013487","journal-title":"Drug Discov Today"},{"key":"BFMSB201147_CR20","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis\u2010Filho JS (2010) Triple\u2010negative breast cancer. N Engl J Med 363: 1938\u20131948","journal-title":"N Engl J Med"},{"key":"BFMSB201147_CR21","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/jnci\/djq390","volume":"102","author":"AN Freedman","year":"2010","unstructured":"Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G et al (2010) Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst 102: 1698\u20131705","journal-title":"J Natl Cancer Inst"},{"key":"BFMSB201147_CR22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1399-5618.2010.00814.x","volume":"12","author":"CS Gau","year":"2010","unstructured":"Gau CS, Chang CJ, Tsai FJ, Chao PF, Gau SS (2010) Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case\u2010control study. Bipolar Disord 12: 253\u2013263","journal-title":"Bipolar Disord"},{"key":"BFMSB201147_CR23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrm1858","volume":"7","author":"LG Griffith","year":"2006","unstructured":"Griffith LG, Swartz MA (2006) Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 7: 211\u2013224","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFMSB201147_CR24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc2571","volume":"9","author":"B Gusterson","year":"2009","unstructured":"Gusterson B (2009) Do \u2018basal\u2010like\u2019 breast cancers really exist? Nat Rev Cancer 9: 128\u2013134","journal-title":"Nat Rev Cancer"},{"key":"BFMSB201147_CR25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/1471-2164-9-394","volume":"9","author":"B Haibe\u2010Kains","year":"2008","unstructured":"Haibe\u2010Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, Van't Veer L, Piccart M, Bontempi G, Sotiriou C (2008) Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 9: 394","journal-title":"BMC Genomics"},{"key":"BFMSB201147_CR26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2164-7-96","volume":"7","author":"Z Hu","year":"2006","unstructured":"Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D et al (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96","journal-title":"BMC Genomics"},{"key":"BFMSB201147_CR27","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","volume":"67","author":"F Huang","year":"2007","unstructured":"Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226\u20132238","journal-title":"Cancer Res"},{"key":"BFMSB201147_CR28","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1073\/pnas.1008990107","volume":"107","author":"EW Joseph","year":"2010","unstructured":"Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF\u2010selective manner. Proc Natl Acad Sci USA 107: 14903\u201314908","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFMSB201147_CR29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molonc.2007.02.004","volume":"1","author":"PA Kenny","year":"2007","unstructured":"Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos\u2010Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three\u2010dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84\u201396","journal-title":"Mol Oncol"},{"key":"BFMSB201147_CR30","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/jco.2010.28.15_suppl.3534","volume":"28","author":"S Kopetz","year":"2010","unstructured":"Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, Nolop KB, Saltz L (2010) PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28 (Suppl): 3534","journal-title":"J Clin Oncol"},{"key":"BFMSB201147_CR31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrc2044","volume":"7","author":"J Lamb","year":"2007","unstructured":"Lamb J (2007) The connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7: 54\u201360","journal-title":"Nat Rev Cancer"},{"key":"BFMSB201147_CR32","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The connectivity Map: using gene\u2010expression signatures to connect small molecules, genes, and disease. Science 313: 1929\u20131935","journal-title":"Science"},{"key":"BFMSB201147_CR33","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/bcr2204","volume":"10","author":"B Marty","year":"2008","unstructured":"Marty B, Maire V, Gravier E, Rigaill G, Vincent\u2010Salomon A, Kappler M, Lebigot I, Djelti F, Tourdes A, Gestraud P, Hupe P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T (2008) Frequent PTEN genomic alterations and activated phosphatidylinositol 3\u2010kinase pathway in basal\u2010like breast cancer cells. Breast Cancer Res 10: R101","journal-title":"Breast Cancer Res"},{"key":"BFMSB201147_CR34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMe068292","volume":"356","author":"J Massague","year":"2007","unstructured":"Massague J (2007) Sorting out breast\u2010cancer gene signatures. N Engl J Med 356: 294\u2013297","journal-title":"N Engl J Med"},{"key":"BFMSB201147_CR35","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.2174\/138161207782360528","volume":"13","author":"M Michaelis","year":"2007","unstructured":"Michaelis M, Doerr HW, Cinatl Jr J (2007) Valproic acid as anti\u2010cancer drug. Curr Pharm Des 13: 3378\u20133393","journal-title":"Curr Pharm Des"},{"key":"BFMSB201147_CR36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"RM Neve","year":"2006","unstructured":"Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515\u2013527","journal-title":"Cancer Cell"},{"key":"BFMSB201147_CR37","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160\u20131167","journal-title":"J Clin Oncol"},{"key":"BFMSB201147_CR38","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen\u2010Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747\u2013752","journal-title":"Nature"},{"key":"BFMSB201147_CR39","unstructured":"PhRMA (2009) Medicines in development for cancer. In http:\/\/www.phrma.org\/files\/attachments\/meds_in_dev\/09\u2010046PhRMACancer09_0331.pdf"},{"key":"BFMSB201147_CR40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1172\/JCI831","volume":"101","author":"RK Ravi","year":"1998","unstructured":"Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, Nelkin BD, Mabry M (1998) Activated Raf\u20101 causes growth arrest in human small cell lung cancer cells. J Clin Invest 101: 153\u2013159","journal-title":"J Clin Invest"},{"key":"BFMSB201147_CR41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1593\/neo.07292","volume":"9","author":"DR Rhodes","year":"2007","unstructured":"Rhodes DR, Kalyana\u2010Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Ghosh D, Varambally S, Chinnaiyan AM (2007) Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9: 443\u2013454","journal-title":"Neoplasia"},{"key":"BFMSB201147_CR42","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr2234","volume":"11","author":"A Rody","year":"2009","unstructured":"Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T\u2010cell metagene predicts a favorable prognosis in estrogen receptor\u2010negative and HER2\u2010positive breast cancers. Breast Cancer Res 11: R15","journal-title":"Breast Cancer Res"},{"key":"BFMSB201147_CR43","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen\u2010Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869\u201310874","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFMSB201147_CR44","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen\u2010Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418\u20138423","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFMSB201147_CR45","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMra0801289","volume":"360","author":"C Sotiriou","year":"2009","unstructured":"Sotiriou C, Pusztai L (2009) Gene\u2010expression signatures in breast cancer. N Engl J Med 360: 790\u2013800","journal-title":"N Engl J Med"},{"key":"BFMSB201147_CR46","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","volume":"68","author":"K Stemke\u2010Hale","year":"2008","unstructured":"Stemke\u2010Hale K, Gonzalez\u2010Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084\u20136091","journal-title":"Cancer Res"},{"key":"BFMSB201147_CR47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2006.05.001","volume":"9","author":"AV Tinker","year":"2006","unstructured":"Tinker AV, Boussioutas A, Bowtell DD (2006) The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 9: 333\u2013339","journal-title":"Cancer Cell"},{"key":"BFMSB201147_CR48","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/JTO.0b013e3181952478","volume":"4","author":"AM Traynor","year":"2009","unstructured":"Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, Wilding G, Espinoza\u2010Delgado I, Schiller JH (2009) Vorinostat (NSC# 701852) in patients with relapsed non\u2010small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 4: 522\u2013526","journal-title":"J Thorac Oncol"},{"key":"BFMSB201147_CR49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10637-008-9131-6","volume":"26","author":"J Vansteenkiste","year":"2008","unstructured":"Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schoffski P (2008) Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non\u2010small cell lung cancer. Invest New Drugs 26: 483\u2013488","journal-title":"Invest New Drugs"},{"key":"BFMSB201147_CR50","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/bcr2124","volume":"10","author":"P Wirapati","year":"2008","unstructured":"Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe\u2010Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M (2008) Meta\u2010analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65","journal-title":"Breast Cancer Res"},{"key":"BFMSB201147_CR51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1152\/physiolgenomics.00193.2004","volume":"20","author":"JR Wood","year":"2005","unstructured":"Wood JR, Nelson\u2010Degrave VL, Jansen E, McAllister JM, Mosselman S, Strauss III JF (2005) Valproate\u2010induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol Genomics 20: 233\u2013243","journal-title":"Physiol Genomics"},{"key":"BFMSB201147_CR52","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbrc.2010.12.088","volume":"404","author":"J Xing","year":"2011","unstructured":"Xing J, Liu R, Xing M, Trink B (2011) The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun 404: 958\u2013962","journal-title":"Biochem Biophys Res Commun"},{"key":"BFMSB201147_CR53","doi-asserted-by":"crossref","first-page":"e1000129","DOI":"10.1371\/journal.pgen.1000129","volume":"4","author":"K Yu","year":"2008","unstructured":"Yu K, Ganesan K, Tan LK, Laban M, Wu J, Zhao XD, Li H, Leung CH, Zhu Y, Wei CL, Hooi SC, Miller L, Tan P (2008) A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet 4: e1000129","journal-title":"PLoS Genet"}],"container-title":["Molecular Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fmsb.2011.47","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/msb.2011.47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1038\/msb.2011.47","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/msb.2011.47\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.1038\/msb.2011.47","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/msb.2011.47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T19:36:22Z","timestamp":1779737782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/msb.2011.47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,19]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7,19]]}},"alternative-id":["BFMSB201147"],"URL":"https:\/\/doi.org\/10.1038\/msb.2011.47","relation":{},"ISSN":["1744-4292"],"issn-type":[{"value":"1744-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,19]]},"assertion":[{"value":"17 January 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"MSB201147"}}